Free cash flow reached $112.7M in 2026Q3 at a 47.9% margin with capital expenditures below 1% of revenue, while $105.0M went to buybacks in 2026Q1 and $97.4M to net acquisitions in 2026Q3, so sustained conversion depends on working capital swings such as the $22.0M and $14.4M inflows in recent quarters.
Hinge Health, Inc. (HNGE) cash flow statement — 3-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 |
|---|
| Cash from Operations | 322.99M | 171.44M | 49M | -63.91M |
| Operating CF Margin % | - | 29.16% | 12.55% | -21.83% |
| Operating CF Growth % | 1281.95% | 249.87% | 176.67% | - |
| Net Income | 168.31M | -528.26M | -11.93M | -108.14M |
| Depreciation & Amortization | 5.68M | 5.13M | 5.95M | 5.63M |
| Stock-Based Compensation | 67.5M | 643.01M | 739K | 1.65M |
| Deferred Taxes | -3.39M | 53K | -585K | -473K |
| Other Non-Cash Items | 71.95M | 53.52M | 41.33M | 28.02M |
| Working Capital Changes | 12.95M | -2.01M | 13.5M | 9.41M |
| Change in Receivables | -58.42M | -26.63M | -1.34M | -23.13M |
| Change in Inventory | -5.08M | -4.76M | 608K | 10.56M |
| Change in Payables | 17.01M | 29.41M | -10.97M | 0 |
| Cash from Investing | -25.17M | -113.76M | 18.31M | 1.5M |
| Capital Expenditures | -2.56M | -708K | -1.04M | -1.98M |
| CapEx % of Revenue | 0.32% | 0.12% | 0.27% | 0.68% |
| Acquisitions | -97.35M | -4M | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | -14.17M | -5.36M | -2.73M | -2.64M |
| Cash from Financing | -345.13M | -150.47M | -2.2M | -3M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | -205.51M | 200.18M | 610K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | -222.41M | -65.03M | 0 | 0 |
| Other Financing | -139.62M | -350.64M | -2.81M | -3M |
| Net Change in Cash | -47.31M | -92.79M | 65.11M | -65.41M |
| Free Cash Flow | 318.7M | 170.73M | 45.23M | -68.52M |
| FCF Margin % | 39.8% | 29.04% | 11.59% | -23.41% |
| FCF Growth % | 125.78% | 277.49% | 166% | - |
| FCF per Share | 3.68 | 2.09 | 0.58 | -0.88 |
| FCF Conversion (FCF/Net Income) | 1.89x | -0.32x | -4.11x | 0.59x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying HNGE stock.
Hinge Health, Inc. (HNGE) generated $171.4M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Hinge Health, Inc. (HNGE) generated $170.7M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Hinge Health, Inc. (HNGE) spent $0.7M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Hinge Health, Inc. (HNGE) spent $65.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Conversion dependent on working capital swings
Metrics are mathematically derived from official filings.
Operating Cash Flow Outpaces Reported Earnings
Based on reported figures, HNGE generated $114.6M of operating cash flow against $57.4M of net income in 2026Q3, an OCF-to-net-income ratio of 2.00 that suggests earnings are being backed by real cash generation rather than accruals.
The ratio held near 2.0 in both 2026Q1 and 2026Q2 aside from a weaker 1.23 in Q1, which points to working capital timing rather than structural weakness. Large non-cash add-backs such as stock-based compensation of $19.5M in the latest quarter contribute to the gap, so the conversion strength partly reflects non-cash expense treatment that investors should keep in view. The sustainability of this conversion depends on whether working capital inflows of $14.4M prove repeatable.
Free Cash Flow Margin Reaches Near Half of Revenue
According to recent SEC filings, HNGE's free cash flow margin reached 47.9% in 2026Q3 after 46.8% in 2026Q2, up sharply from 15.6% in 2024Q2, indicating a rapid shift toward self-funding operations.
Capital expenditure is negligible at 0.8% of revenue, so nearly all operating cash converts into free cash flow, which makes the margin more sensitive to working capital and SBC treatment than to investment needs. The move from a near-breakeven Q1 2025 FCF of $4.2M to $112.7M in the latest quarter signals meaningful operating leverage. Investors should monitor whether margins hold once working capital tailwinds fade.
Asset-Light Model Limits Reinvestment Needs
Based on reported figures, HNGE's capital expenditures remained below 1% of revenue across the last several quarters, with the latest quarter at $1.9M, consistent with a platform business that delivers care largely through software and contracted clinicians.
The minimal capex profile implies that the company's cash needs are driven by operating expenses such as clinical labor and customer acquisition rather than fixed asset investment. Depreciation and amortization of $2.2M in 2026Q3 sits well above capex, which may reflect amortization of previously capitalized development or hardware, warranting further investigation into the accounting for those assets. Low capital intensity supports high cash conversion but leaves the model exposed to any future hardware refresh cycle.
Cash Directed Toward Buybacks and Acquisitions
As reported in financial statements, HNGE deployed $105.0M into share repurchases in 2026Q1 and $97.4M into net acquisitions in 2026Q3, with no dividends paid across the period shown.
Capital deployment has shifted from balance sheet accumulation toward active buybacks and acquisitions once free cash flow scaled, which suggests management views internally generated cash as sufficient to fund both. The lumpy pattern of repurchases, with $65.0M in Q4 2025 and $25.9M in Q3 2026 among other quarters, indicates opportunistic rather than programmatic execution. Returns on these acquisitions cannot be assessed from the supplied data and warrant further review.
Cumulative Cash Reality Lags Net Income Volatility
Based on reported figures, HNGE's 2025Q2 net loss of $575.7M was driven by a $591.0M non-cash charge, while operating cash flow stayed positive at $20.2M, illustrating how reported earnings and cash generation have diverged sharply in individual quarters.
Over the 10-quarter window, the pattern of large GAAP swings alongside steadily rising operating cash flow suggests the reported net income series is distorted by non-cash items rather than reflecting underlying cash economics. The $121.3M net income in 2025Q1, far above its operating result, further indicates non-operating gains that do not translate to cash. An analyst should treat the cumulative cash series as the more reliable indicator of earnings power.
Stock-Based Compensation Flatters Cash Metrics
According to recent SEC filings, HNGE's operating cash flow adds back $19.5M of stock-based compensation in 2026Q3, meaning a portion of the cash strength reflects equity dilution rather than cash-costed labor and sales expense.
Because SBC is excluded from operating cash flow, free cash flow margins of 47.9% may overstate the economic cash generated for shareholders once dilution is considered. The 2025Q2 SBC figure of $591.0M also suggests a very large equity-related charge that bears watching for future dilution impact. Investors should evaluate free cash flow after SBC to gauge true owner economics, which may materially reduce the headline margin.